Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

100,194 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ontogeny and sorafenib metabolism.
Zimmerman EI, Roberts JL, Li L, Finkelstein D, Gibson A, Chaudhry AS, Schuetz EG, Rubnitz JE, Inaba H, Baker SD. Zimmerman EI, et al. Among authors: li l. Clin Cancer Res. 2012 Oct 15;18(20):5788-95. doi: 10.1158/1078-0432.CCR-12-1967. Epub 2012 Aug 27. Clin Cancer Res. 2012. PMID: 22927483 Free PMC article. Clinical Trial.
Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.
Inaba H, Rubnitz JE, Coustan-Smith E, Li L, Furmanski BD, Mascara GP, Heym KM, Christensen R, Onciu M, Shurtleff SA, Pounds SB, Pui CH, Ribeiro RC, Campana D, Baker SD. Inaba H, et al. Among authors: li l. J Clin Oncol. 2011 Aug 20;29(24):3293-300. doi: 10.1200/JCO.2011.34.7427. Epub 2011 Jul 18. J Clin Oncol. 2011. PMID: 21768474 Free PMC article. Clinical Trial.
Alternative formulations of sorafenib for use in children.
Navid F, Christensen R, Inaba H, Li L, Chen Z, Cai X, Regel J, Baker SD. Navid F, et al. Among authors: li l. Pediatr Blood Cancer. 2013 Oct;60(10):1642-6. doi: 10.1002/pbc.24619. Epub 2013 Jun 20. Pediatr Blood Cancer. 2013. PMID: 23788485 Free PMC article. Clinical Trial.
Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory/Relapsed Leukemia or Solid Tumor Malignancies.
Inaba H, Panetta JC, Pounds SB, Wang L, Li L, Navid F, Federico SM, Eisenmann ED, Vasilyeva A, Wang YD, Shurtleff S, Pui CH, Gruber TA, Ribeiro RC, Rubnitz JE, Baker SD. Inaba H, et al. Among authors: li l. Clin Cancer Res. 2019 Dec 15;25(24):7320-7330. doi: 10.1158/1078-0432.CCR-19-0470. Epub 2019 Aug 27. Clin Cancer Res. 2019. PMID: 31455680 Free PMC article.
Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and FLT3-Internal Tandem Duplication.
Inaba H, van Oosterwijk JG, Panetta JC, Li L, Buelow DR, Blachly JS, Shurtleff S, Pui CH, Ribeiro RC, Rubnitz JE, Pounds S, Baker SD. Inaba H, et al. Among authors: li l. Clin Cancer Res. 2022 Jun 13;28(12):2536-2546. doi: 10.1158/1078-0432.CCR-21-4450. Clin Cancer Res. 2022. PMID: 35344039 Free PMC article.
Cisplatin-induced renal injury is independently mediated by OCT2 and p53.
Sprowl JA, Lancaster CS, Pabla N, Hermann E, Kosloske AM, Gibson AA, Li L, Zeeh D, Schlatter E, Janke LJ, Ciarimboli G, Sparreboom A. Sprowl JA, et al. Among authors: li l. Clin Cancer Res. 2014 Aug 1;20(15):4026-35. doi: 10.1158/1078-0432.CCR-14-0319. Epub 2014 Jun 10. Clin Cancer Res. 2014. PMID: 24916697 Free PMC article.
100,194 results
You have reached the last available page of results. Please see the User Guide for more information.